How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

211 results for

Ciclopirox

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails

contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Four antifungal agents for the treatment of onychomycosis of the toenails and fingernails were considered. The oral and topical therapies assessed were itraconazole-continuous, itraconazole-pulse, terbinafine and ciclopirox. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study (...) combined using a meta-analysis. Investigation of differences between primary studies The authors reported that consensus about differences between the studies was reached through discussion. Results of the review The success rates were: with itraconazole-continuous, 0.926 for fingernail and 0.645 for toenail; with itraconazole-pulse, 0.793 for fingernail and 0.565 for toenail; with terbinafine, 0.965 for fingernail and 0.811 for toenail; and with ciclopirox, 0.321 for toenail (the success rate

2003 NHS Economic Evaluation Database.

162. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany

EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of antifungal agents in the treatment of patients with toenail onychomycosis. The agents considered were as follows: (1)itraconazole, continuous regimen, (2) itraconazole, 1-week pulse dosage regimen, (3) oral terbinafine, (4) topical ciclopirox nail varnish. Type of intervention (...) % (+/- 10%); ciclopirox nail varnish, 55.0% (+/- 4%). Methods used to derive estimates of effectiveness Estimates of effectiveness were also based on authors' assumptions. Estimates of effectiveness and key assumptions The efficacy rate of the second line therapy was assumed to be an average of the two most effective antifungal agents (pulsed itraconazole and oral terbinafine). Relapse rates were not included in the analysis because of lack of sufficient data on itraconazole therapies. Measure

1996 NHS Economic Evaluation Database.

163. Is there any evidence of a better cure rate for treating proven fungal toe nail infections with both oral and topical preparations?

therapy can be advocated.” The recent RCT was published in 2005 looked at Ciclopirox topical solution combined with terbinafine to treat onychomycosis [6]. 73 patients were randomised to 1 of 3 treatment arms: ciclopirox nail lacquer once daily for 48 weeks plus 4 weeks of terbinafine 250 mg/day, followed by 4 weeks of rest (no terbinafine), then another 4 weeks of terbinafine 250 mg/day (PLs); ciclopirox nail lacquer once daily for 48 weeks plus terbinafine 250 mg/day for 12 weeks (PL12 (...) Combination Therapy Study Group. Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study. Drugs Dermatol. 2005 Jul-Aug;4(4):481-5. ( ) Answered 9 February 2006 Follow us: © 2019 Trip Database Ltd. company number 04316414. Trip is proud to be made in the UK.

2006 TRIP Answers

164. Increased Endogenous Nitric Oxide Release by Iron Chelation and Purinergic Activation in the Rat Carotid Body (PubMed)

by microsensor inserted into the isolated carotid body superfused with bicarbonate-buffer were examined. Suramin did not change the resting NO level under normoxic conditions but it significantly decreased the hypoxia-induced NO elevation in a dose-dependent manner. Suramin (100muM) blocked the NO response to acute hypoxia by 53%. Intracellular iron chelator, ciclopirox olamine (CPX) significantly increased the resting NO release close to the hypoxic level, which was reversed by FeSO(4) or blocked by L-NMMA

Full Text available with Trip Pro

2007 The Open Biochemistry Journal

165. Dermacase. Pityriasis rosea. (PubMed)

Dermacase. Pityriasis rosea. 14761101 2004 02 24 2018 11 30 0008-350X 50 2004 Jan Canadian family physician Medecin de famille canadien Can Fam Physician Dermacase. Pityriasis rosea. 41, 49-50 Turchin Irina I Faculty of Medicine, University of Calgary, Alberta. Adams Stewart P SP Enta Tom T eng Case Reports Journal Article Canada Can Fam Physician 0120300 0008-350X 0 Antifungal Agents 0 Pyridones 19W019ZDRJ Ciclopirox IM Acute Disease Adolescent Antifungal Agents therapeutic use Ciclopirox

Full Text available with Trip Pro

2004 Canadian Family Physician

166. Can the use of a topical antifungal nail lacquer reduce risk for diabetic foot ulceration? Results from a randomised controlled pilot study. (PubMed)

involving daily self-inspection with the possible use of an AFL (ciclopirox 8%) versus self-inspection instructions alone (NAFL). Patients were followed for 12 months or until ulceration. Using an intent to treat analysis, there was no significant difference in proportion of persons ulcerating in the AFL versus the NAFL groups (5.9% versus 5.6% P = 0.9). There was also no difference in the number of unexpected visits (P = 0.2) or missed appointments (P = 0.7) between treatment arms. Interestingly, while

2005 International wound journal

167. A case report of Hailey-Hailey disease treated with alefacept (Amevive((R))). (PubMed)

ciclopirox, tazarotene cream, pimecrolimus cream and tacrolimus ointment. Partial response of this patient's perineal disease was achieved with Amevive 15 mg weekly for 12 weeks, intramuscularly. To our knowledge, this case represents the first such published report of successful treatment of Hailey-Hailey disease using alefacept.

2007 British Journal of Dermatology

168. Cost-effectiveness of diagnostic tests for toenail onychomycosis: a repeated-measure, single-blinded, cross-sectional evaluation of 7 diagnostic tests. (PubMed)

, use of oral antifungal medication for 2 months or longer within the past year, or topical ciclopirox lacquer within 6 weeks of enrollment. The main outcome measure was the cost-effectiveness (Medicare and non-Medicare costs) of 7 diagnostic tests. Sensitivity (at least 3 positive tests) was the unit of effectiveness.Two hundred four participants were enrolled; their average age was 69.5 years and 95.5% were male. PAS was the most sensitive test (98.8%); it was statistically significantly more

2006 Journal of American Academy of Dermatology

169. Eukaryotic initiation factor 5A-1 (eIF5A-1) as a diagnostic marker for aberrant proliferation in intraepithelial neoplasia of the vulva. (PubMed)

lacked reactive cells.NIH-353 identifies mature eIF5A-1 as an in situ biomarker for proliferation. Like Ki-67, this immunoreagent promises broad applicability in histopathological diagnosis and may be helpful in outcome prediction. In contrast to Ki-67, NIH-353 visualizes a molecular target for antineoplastic therapy, and thus may guide the development and clinical testing of drugs that, like the fungicide ciclopirox, inhibit hypusine formation and cell proliferation.

2004 Gynecologic Oncology

170. Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails. (PubMed)

cost-effective agent.A decision analytic model was developed to evaluate the pharmacoeconomic profiles of itraconazole-continuous (Sporanox, Janssen Pharmaceutica), itraconazole-pulse (Sporanox, Janssen Pharmaceutica), terbinafine (Lamisil, Novartis Pharmaceuticals), and ciclopirox (Penlac, Dermik Laboratories) in the treatment of fingernail and toenail onychomycosis.We conducted a meta-analysis of the available literature to populate the decision analytic model with clinical point estimates

2003 Managed care (Langhorne, Pa.)

171. [A comparative double blind trial with vaginal creams of cyclopyroxolamine and miconazole in vulvovaginal candidosis (author's transl)]. (PubMed)

Ciclopiroxolamin- und miconazol-Vaginalcreme bei vulvovaginaler Candidose. Germany Mykosen 0400765 0027-5557 0 Imidazoles 0 Pyridones 0 Vaginal Creams, Foams, and Jellies 19W019ZDRJ Ciclopirox 7NNO0D7S5M Miconazole IM Adult Candidiasis, Vulvovaginal drug therapy Ciclopirox Double-Blind Method Female Humans Imidazoles therapeutic use Miconazole therapeutic use Middle Aged Pregnancy Pyridones therapeutic use Vaginal Creams, Foams, and Jellies 1981 12 1 2000 6 1 9 0 1981 12 1 0 0 ppublish 7335112

1982 Mykosen

172. Simplified experimental human dermatophytosis model. (PubMed)

ciclopirox olamine formulations. The lesions, easily induced by the authors' method, were localized and did not spread under the occlusive dressings. Infections established at the four sites on 26 subjects were treated twice daily for 14 days with the two active drug formulations and their vehicles. There were no significant differences in culture-documented cure rates or alleviation of clinical signs and symptoms between ciclopirox olamine lotion and cream. Each drug was significantly better than its

1992 International journal of dermatology

173. Anti-inflammatory activity of antifungal preparations. (PubMed)

-blind, controlled protocol, we assessed the comparative ability of antifungal preparations to suppress the expected delayed erythema response following in vivo human exposure to ultraviolet B (UVB) irradiation generated by a solar stimulator.Currently available allylamine preparations and ciclopirox olamine proved to be the most anti-inflammatory, while ketoconazole was intermediate in anti-inflammatory activity under these experimental conditions. These agents were superior to oxiconazole

1997 International journal of dermatology

174. Pharmacoeconomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as an example. (PubMed)

variance is produced, along with a 95% confidence interval. This method can be applied to any set of proportions. In the example, the success rate of ciclopirox lacquer was 81.6% (standard error, 3.5%) and of amorolfine lacquer was 71.4% (standard error, 2.3%). A stricter definition of success (ie, cure only) produced success rates of 31.3% (standard error, 2.4%) and 35.8% (standard error, 1.9%), respectively. This stepwise approach for combining single proportions is suggested as a useful method

1997 Clinical therapeutics

175. Treatment of dermatophyte toenail onychomycosis in the United States. A pharmacoeconomic analysis. (PubMed)

Treatment of dermatophyte toenail onychomycosis in the United States. A pharmacoeconomic analysis. This study attempted to determine the cost-effectiveness of therapies for dermatophyte toenail onychomycosis in the United States in 2001. The antimycotic agents evaluated were ciclopirox 8% nail lacquer and the oral agents terbinafine, itraconazole (pulse), itraconazole (continuous), fluconazole, and griseofulvin. A treatment algorithm for the management of onychomycosis was developed, and a meta (...) -analysis was carried out to determine the average mycologic and clinical response rates for the various agents. The cost of the regimen was figured as the sum of the costs of drug acquisition, medical management, and management of adverse effects. The expected cost of management and disease-free days were determined, and a sensitivity analysis was conducted. It was concluded that ciclopirox 8% nail lacquer, which has recently become available in the larger size of 6.6 mL, is a cost-effective agent

2002 Journal of the American Podiatric Medical Association

176. In vitro activity of ME1401, a new antifungal agent. (PubMed)

In vitro activity of ME1401, a new antifungal agent. The in vitro antifungal activity of ME1401, a potential topical antifungal agent, was compared with that of haloprogin, clotrimazole, miconazole, tolnaftate, and ciclopirox olamine by using an agar dilution procedure. ME1401 showed a broad antifungal spectrum and inhibited all of the 428 strains of 52 species of pathogenic yeasts and filamentous fungi tested at concentrations ranging from 0.01 to 12.5 micrograms/ml. In general, the activity

Full Text available with Trip Pro

1986 Antimicrobial Agents and Chemotherapy

177. [Treatment onychomycoses--bifonazole nail set in comparison with urea with ciclopiroxolamine formulation]. (PubMed)

Harnstoffrezeptur mit Ciclopiroxolamin. Germany Z Arztl Fortbild (Jena) 0414004 0044-2178 0 Antifungal Agents 0 Pharmaceutical Vehicles 0 Pyridones 19W019ZDRJ Ciclopirox 8W8T17847W Urea IM Administration, Topical Adult Aged Antifungal Agents administration & dosage Ciclopirox Female Humans Male Middle Aged Onychomycosis drug therapy Pharmaceutical Vehicles Pyridones administration & dosage Urea administration & dosage 1993 4 12 2000 6 1 9 0 1993 4 12 0 0 ppublish 8322470

1993 Zeitschrift fur arztliche Fortbildung

178. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States

Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States (...) Gupta A K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of ciclopirox 8% (continuous therapy), a novel topical lacquer, for the treatment of onychomycosis of the toe. Type of intervention Treatment. Economic study type

2000 NHS Economic Evaluation Database.

179. Selenium Sulfide, Ketoconazole and Ciclopirox Shampoo as Additional Treatments for Tinea Capitis (Scalp Ringworm)

Selenium Sulfide, Ketoconazole and Ciclopirox Shampoo as Additional Treatments for Tinea Capitis (Scalp Ringworm) Selenium Sulfide, Ketoconazole and Ciclopirox Shampoo as Additional Treatments for Tinea Capitis (Scalp Ringworm) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Selenium Sulfide, Ketoconazole and Ciclopirox Shampoo as Additional Treatments for Tinea Capitis (Scalp Ringworm) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00127868 Recruitment Status : Completed First Posted : August 9, 2005

2005 Clinical Trials

180. Successful treatment of dandruff with 1.5% ciclopirox olamine shampoo in Korea. (PubMed)

Successful treatment of dandruff with 1.5% ciclopirox olamine shampoo in Korea. Dandruff is a chronic scalp condition characterized by scaling. The common causative agent is now accepted to be the lipophilic yeast Malassezia furfur. Ketoconazole, a highly effective antifungal agent against M. furfur has been used for the treatment of dandruff.To determine whether a 1.5% ciclopirox olamine shampoo is as effective as a 2% ketoconazole shampoo for the treatment of mild to moderate dandruff.A total (...) of 64 patients, with mild to moderate dandruff, participated in the study. The study consisted of three consecutive phases: a 2-week washout period, a 4-week treatment period and a 2-week post-treatment period. Patients were randomized equally to either the 1.5% ciclopirox olamine shampoo or 2% ketoconazole shampoo. An overall dandruff score was calculated using an area of dandruff involvement score and a severity score. Patients evaluated the presence of pruritus and also reported a global

2003 Journal of Dermatological Treatment

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>